Evidence map›Paper›PMID 39418292›Full record

ArticlePLoS biology2024

Chromatin remodeller Chd7 is developmentally regulated in the neural crest by tissue-specific transcription factors.

Ruth M Williams, Guneş Taylor, Irving T C Ling, Ivan Candido-Ferreira, Daniel M Fountain, Sarah Mayes, Perihan Seda Ateş-Kalkan, Julianna O Haug, Andrew J Price, Sean A McKinney and 5 more

Abstract read
In one paragraph

Article in PLoS biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ruth M WilliamsStowers Institute for Medical Research, Kansas City, Missouri, United States of America.ORCID 0000-0002-2628-7834
Guneş TaylorUniversity of Oxford, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford, United Kingdom.
Irving T C LingUniversity of Oxford, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford, United Kingdom.
Ivan Candido-FerreiraStowers Institute for Medical Research, Kansas City, Missouri, United States of America.
Daniel M FountainUniversity of Oxford, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford, United Kingdom.
Sarah MayesUniversity of Oxford, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford, United Kingdom.
Perihan Seda Ateş-KalkanStowers Institute for Medical Research, Kansas City, Missouri, United States of America.
Julianna O HaugStowers Institute for Medical Research, Kansas City, Missouri, United States of America.
Andrew J PriceStowers Institute for Medical Research, Kansas City, Missouri, United States of America.
Sean A McKinneyStowers Institute for Medical Research, Kansas City, Missouri, United States of America.
Yavor K BozhilovhUniversity of Oxford, MRC WIMM Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom.
Richard C V TyserUniversity of Oxford, Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford, United Kingdom.
Shankar SrinivasUniversity of Oxford, Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford, United Kingdom.
Jim R HughesUniversity of Oxford, MRC WIMM Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom.
Tatjana Sauka-SpenglerStowers Institute for Medical Research, Kansas City, Missouri, United States of America.ORCID 0000-0001-9289-0263

Funding

Wellcome Trust
6 · The paper itself

Abstract

Neurocristopathies such as CHARGE syndrome result from aberrant neural crest development. A large proportion of CHARGE cases are attributed to pathogenic variants in the gene encoding CHD7, chromodomain helicase DNA binding protein 7, which remodels chromatin. While the role for CHD7 in neural crest development is well documented, how this factor is specifically up-regulated in neural crest cells is not understood. Here, we use epigenomic profiling of chick and human neural crest to identify a cohort of enhancers regulating Chd7 expression in neural crest cells and other tissues. We functionally validate upstream transcription factor binding at candidate enhancers, revealing novel epistatic relationships between neural crest master regulators and Chd7, showing tissue-specific regulation of a globally acting chromatin remodeller. Furthermore, we find conserved enhancer features in human embryonic epigenomic data and validate the activity of the human equivalent CHD7 enhancers in the chick embryo. Our findings embed Chd7 in the neural crest gene regulatory network and offer potentially clinically relevant elements for interpreting CHARGE syndrome cases without causative allocation.

Indexed as

DNA-Binding ProteinsGene Expression Regulation, DevelopmentalNeural CrestTranscription FactorsAnimalsCHARGE SyndromeChick EmbryoChromatin Assembly and DisassemblyDNA HelicasesEnhancer Elements, GeneticGene Regulatory NetworksHumansOrgan SpecificityCHD7 protein, humanDNA-Binding ProteinsDNA HelicasesTranscription Factors

Identifiers

PMID39418292
PMCPMC11521297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.